AbbVie (ABBV) Stock News

Guggenheim maintained its price target for AbbVie at $288.00 per share.

JP Morgan increased its price target for AbbVie to $300.00 per share.

The FDA granted Breakthrough Therapy Designations for AbbVie's investigational ADC Temab-A in colorectal cancer (combo with bevacizumab) and non-small cell lung cancer (monotherapy). The designations are based on Phase 1 data and mark the first BTDs for this asset.

Phase 3 EPCORE DLBCL-2 trial met primary endpoint; epcoritamab + R-CHOP reduced risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL patients with IPI 2-5. Safety consistent. Companies to engage regulators.

The charge will lower reported third-quarter earnings per share. AbbVie did not provide further details.

AbbVie's fiscal year outlook is below consensus, according to a Dow Jones report. No further details were provided.

AbbVie disclosed a preliminary $216 million acquired IPR&D and milestones expense for Q3 2026, reducing both GAAP and adjusted diluted EPS by $0.11. The company updated its Q3 adjusted EPS guidance range to $3.73-$3.77 and full-year 2026 adjusted EPS range to $13.76-$13.96, including the impact. The expense relates to collaborations and licensing deals executed during the quarter.

Genmab and AbbVie reported a 51% reduction in the risk of disease progression or death in a clinical trial. No further details were immediately available.

AbbVie said JUVMO (tavapadon) tablets are available in 5 mg, 10 mg, and 15 mg strengths, plus a titration pack containing 0.25 mg and 1 mg tablets. The drug was approved for Parkinson's disease earlier today.

AbbVie announced FDA approval of JUVMO (tavapadon), the first selective D1/D5 receptor agonist for adults with Parkinson's disease. The once-daily tablet is supported by Phase 3 TEMPO data showing improved motor control and reduced levodopa dose escalation. AbbVie expects U.S. availability in October 2026.

FDA clears AbbVie's Juvmo (tavapadon) for adults with Parkinson's disease.

Health Canada approved AbbVie's Epkinly for adults with follicular lymphoma.

AbbVie reports positive late-stage results for a preventive treatment aimed specifically at menstrual migraine.

Piper Sandler increased its price target on AbbVie to $303 from $298. The new target implies a slight upside from the prior level. No additional details were provided.